Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Young Hak Kim, Makoto Nishio, Hiroshige Yoshioka, Hiroshi Nokihara, Miyako Satouchi, Kazuhiko Nakagawa, Toru Kumagai, Takashi Seto, Katsuyuki Hotta, Masahiro Morise, Toyoaki Hida, Satoshi Watanabe, Nobuyuki Yamamoto, Tetsuya Mitsudomi, Takuya Yoshimoto, Koichi Azuma, Tomohide Tamura, Koichi Goto, Yuichi Takiguchi, Toshiyuki Kozuki
Publikováno v:
Journal of Clinical Oncology. 39:9022-9022
9022 Background: The primary analysis of the J-ALEX (JapicCTI-132316) study for the ALK-inhibitor naïve ALK+ NSCLC demonstrated superior progression-free survival (PFS) in Japanese patients randomized to the ALC, compared with those assigned in the
Autor:
Masahiko Ando, Yukio Hosomi, Toyoaki Hida, Tsuneo Shimokawa, Yuichiro Ohe, Yuki Misumi, Ryunosuke Machida, Kazuhiko Nakagawa, Tomoko Kataoka, Isamu Okamoto, Hiroshi Tanaka, Hiroaki Akamatsu, Hidehito Horinouchi, Shinji Atagi, Kaoru Kubota, Junko Eba, Hiroaki Okamoto, Koichi Goto
Publikováno v:
Journal of Clinical Oncology. 39:8571-8571
8571 Background: Carboplatin and etoposide is the current standard treatment for elderly extensive-disease small-cell lung cancer (ED-SCLC). The purpose of this study is to evaluate the efficacy and safety of carboplatin and irinotecan compared with
Autor:
Tomohide Tamura, Naoyuki Nogami, Masao Harada, Haruyasu Murakami, Hiroshige Yoshioka, Yuichiro Ohe, Akira Inoue, Makoto Nishio, Kengo Takeuchi, Takashi Seto, Hiroshi Kuriki, Katsuyuki Kiura, Makoto Maemondo, Tadashi Shimada, Kazuhiko Nakagawa, Toyoaki Hida, Tomohiro Tanaka
Publikováno v:
Journal of Clinical Oncology
Purpose Alectinib is an anaplastic lymphoma kinase (ALK) –specific kinase inhibitor that seems to be effective against non–small-cell lung cancer (NSCLC) with a variety of ALK mutations. The primary analysis of AF-001JP reported a promising overa
Autor:
Junichi Shimizu, Tatsuya Yoshida, Yukinori Sakao, Yoshitsugu Horio, Yasushi Yatabe, Yuko Oya, Toyoaki Hida, Hiroaki Kuroda, Kosuke Tanaka
Publikováno v:
Journal of Clinical Oncology. 34:3383-3389
Purpose Anaplastic lymphoma kinase (ALK) rearrangement–positive non–small-cell lung cancers can be effectively treated with an ALK tyrosine kinase inhibitor (TKI) such as crizotinib, but the response magnitude and duration are heterogeneous. Seve
Autor:
Makoto Nishio, Jie Zhang, Chetachi Emeremni, Myung-Ju Ahn, Lucio Crinò, David R. Spigel, Tony Mok, Toyoaki Hida, Enriqueta Felip, Filippo de Marinis, Massimiliano Quadrigli, Giorgio V. Scagliotti, Alice T. Shaw, Fabrice Branle, Heather A. Wakelee, Harry J.M. Groen
Publikováno v:
Journal of Clinical Oncology, 34(24), 2866-2878. AMER SOC CLINICAL ONCOLOGY
Purpose Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged non–small-cell lung cancer (NSCLC), regardless of brain metastases status and with or without prior therapy with an inhibitor of the ALK protein. Data are pre
Autor:
Monette Villalobos, Filippo de Marinis, David R. Spigel, Dolores Isla, Ida Berglin Enquist, Simonetta Mocci, Yu Deng, Jacek Jassem, Tibor Csőszi, See Phan, Gongyan Chen, Xiaohui Wen, Toyoaki Hida, Hina Patel, Jacques Cadranel, Diego Cortinovis, Giuseppe Giaccone, Roy S. Herbst, Hiroshi Kuriki, Konstantinos N. Syrigos
Publikováno v:
Journal of Clinical Oncology. 38:e21623-e21623
e21623 Background: IMpower110 evaluated atezo mono in PD-L1–selected, chemo-naive patients (pts) with nonsquamous (nsq) or squamous (sq) NSCLC. At the interim analysis, IMpower110 met its primary OS endpoint, with a statistically significant and cl
Autor:
Yuichiro Ohe, Koichi Goto, Makoto Nishio, Ryo Toyozawa, Tadasuke Shimokawaji, Takayuki Asato, Toyoaki Hida, Takashi Seto, Toru Kumagai, Pingkuan Zhang, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Tatsuya Yoshida, Kentarou Kudou
Publikováno v:
Journal of Clinical Oncology. 38:9537-9537
9537 Background: Brigatinib is an ALK inhibitor with demonstrated activity against ALK resistance mutations. To evaluate efficacy and safety in Japanese patients with ALK-positive non-small cell lung cancer (NSCLC), a prospective, single-arm, phase 2
Autor:
Natasha B. Leighl, Santiago Ponce Aix, Lecia V. Sequist, Leslie O’Sullivan-Djentuh, Monica Giovannini, Sang-We Kim, Christian Grohé, Daniel Shao-Weng Tan, Enriqueta Felip, James Chih-Hsin Yang, Samson Ghebremariam, Riccardo Belli, Juergen Wolf, Gregory J. Riely, Egbert F. Smit, Toyoaki Hida, Dong Wan Kim, Ryo Toyozawa
Publikováno v:
Journal of Clinical Oncology. 38:9574-9574
9574 Background: Prior data from a phase I/II study showed durable responses, including efficacy in brain lesions, and a tolerable safety profile with nazartinib in treatment (tx)-naïve patients (pts) with EGFR-mutant (mut), locally advanced (adv)/m
Autor:
Tomohide Tamura, Tetsuya Mitsudomi, Toshiyuki Kozuki, Hiroshi Nokihara, Koichi Goto, Young Hak Kim, Toyoaki Hida, Koichi Azuma, Takashi Asakawa, Nobuyuki Yamamoto, Miyako Satouchi, Kazuhiko Nakagawa, Makoto Nishio, Masahiro Morise, Katsuyuki Hotta, Hiroshige Yoshioka, Takashi Seto, Satoshi Watanabe, Toru Kumagai, Yuichi Takiguchi
Publikováno v:
Journal of Clinical Oncology. 37:9092-9092
9092 Background: The primary analysis of the J-ALEX (JapicCTI-132316) study for the ALK-inhibitor naïve ALK+ NSCLC demonstrated superior progression-free survival (PFS) of ALC compared with CRZ (HR 0.34, 99.7% CI 0.17–0.71, stratified log-rank p <
Autor:
Daniel Shao-Weng Tan, Egbert F. Smit, Harry J.M. Groen, Rebecca S. Heist, Toyoaki Hida, Pierre Jean Souquet, Juergen Wolf, Sylvie Le Mouhaer, Monica Giovannini, Edward B. Garon, Anna Robeva, Sergey Orlov, Maja J.A. de Jonge, M. Waldron-Lynch, Ji-Youn Han, Takashi Seto, Noemí Reguart, Johan Vansteenkiste
Publikováno v:
Journal of Clinical Oncology. 37:9004-9004
9004 Background: Capmatinib is a highly potent and selective MET inhibitor. Previous data of GEOMETRY mono-1 study showed a clinically meaningful overall response rate (ORR) and manageable toxicity profile in patients (pts) with METΔex14–mutated N